Cenegermin can be adjunctive therapy for neurotrophic keratitis treatment
Click Here to Manage Email Alerts
Recombinant human nerve growth factor is an effective adjunct therapy when used with corneal transplantation for the treatment of neurotrophic keratitis, according to a speaker at the virtual Wills Eye Conference.
“Cenegermin as a novel treatment should be considered as an effective adjunct therapy and to be considered in use with patients treated with penetrating keratoplasty in the setting of neurotrophic keratitis,” Ashley Khalili, MD, said.
Khalili and colleagues conducted a retrospective case series including patients treated with cenegermin within 10 months of undergoing high-risk penetrating keratoplasty. The study included nine patients. Herpes simplex virus was the most common cause of neurotrophic keratitis, accounting for one-third of the included cases, Khalili said.
The average time between PK and the start of cenegermin treatment was 4 months, with a mean of 4 months until treatment follow-up.
“Some of these patients were prescribed to start right at the time of the penetrating keratoplasty but were delayed due to those types of logistical reasons, while some just had poor healing despite the amniotic membrane transplant and therefore it was decided to start afterward,” Khalili said.
The patients with at least 1 month of follow-up all had full resolution of any epithelial defect with no visible staining. There were no episodes of graft failure at 1 month, but data suggest a possibility of two cases of graft failure before the 6-month follow-up.
Collapse
Khalili A, et al. Recombinant human nerve growth factor (RHNGF) in the management of high-risk penetrating keratoplasty. Presented at: Wills Eye Conference; March 12, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts